Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia

NCT01408732 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Epistaxis
Hereditary Hemorrhagic Telangiectasia

Interventions

DRUG: Sclerotherapy
OTHER: Standard Treatment

Sponsor

University of Minnesota

Collaborators

[object Object]